Publications by authors named "Mette B Levring"

Claim this Profile
I
Ixazomib treatment has a dual effect on bone remodeling in patients with multiple myeloma: follow-up results from a phase 2 clinical study.
Mette Bøegh Levring, Marta Diaz-delCastillo, Michael Tveden Gundesen, Oriane Cédile, Christian Walther Andersen

Bone· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The real-world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies.
Agoston Gyula Szabo, Jonathan Thorsen, Katrine Fladeland Iversen, Mette Bøegh Levring, Carsten Helleberg

EJHaem· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease.
Martin Johansen, Mette Bøegh Levring, Kasper Stokbro, Marta Diaz-delCastillo, Abdul Ahad Khan

Cancers (Basel)· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 antibody kinetics in blood donors with a previously positive SARS-CoV-2 antibody test within a seroprevalence survey.
Mette B Levring, Dorte K Holm, Anna C Nilsson, Joschka M Bauer, Iben S Jensen

J Med Virol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy.
Agoston Gyula Szabo, Jonathan Thorsen, Katrine Fladeland Iversen, Mette Bøegh Levring, Birgitte Preiss

Am J Hematol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The real-world outcomes of multiple myeloma patients treated with daratumumab.
Agoston Gyula Szabo, Tobias Wirenfeldt Klausen, Mette Bøegh Levring, Birgitte Preiss, Carsten Helleberg

PLoS One· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients.
Karen Louise Højholt, Henrik Gregersen, Agoston Gyula Szabo, Tobias Wirenfeldt Klausen, Mette Bøegh Levring

Hematol Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis